Lin Bioscience

Lin Bioscience Net Income

The Net Income of Lin Bioscience (6696.TWO) as of Nov 22, 2026 is -1.36 B TWD. In the previous year, Net Income was -744.27 M TWD — a change of 83.11% (lower).

Net Income

-1.36 BTWD

YoY

83.11%

Last updated:

In 2025, Lin Bioscience's profit amounted to -1.36 B TWD, a 83.11% increase from the -744.27 M TWD profit recorded in the previous year.

The Lin Bioscience Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2018
-138.52 M TWD
Jan 1, 2019
-235.26 M TWD
Jan 1, 2020
-151.84 M TWD
Jan 1, 2021
-434.70 M TWD
Jan 1, 2022
-313.52 M TWD
Jan 1, 2023
-687.19 M TWD
Jan 1, 2024
-744.27 M TWD
Jan 1, 2025
-1.36 B TWD
The Lin Bioscience Net Income history
YEARNet IncomeYoY
-1.36 BTWD+83.11%
-744.27 MTWD+8.31%
-687.19 MTWD+119.18%
-313.52 MTWD-27.88%
-434.70 MTWD+186.28%
-151.84 MTWD-35.46%
-235.26 MTWD+69.84%
-138.52 MTWD-12.95%
-159.12 MTWD+277.15%
-42.19 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lin Bioscience Revenue

Lin Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 TWD
-155.60 M TWD
-138.52 M TWD
Jan 1, 2019
0.00 TWD
-238.22 M TWD
-235.26 M TWD
Jan 1, 2020
0.00 TWD
-196.99 M TWD
-151.84 M TWD
Jan 1, 2021
0.00 TWD
-338.28 M TWD
-434.70 M TWD
Jan 1, 2022
0.00 TWD
-445.13 M TWD
-313.52 M TWD
Jan 1, 2023
0.00 TWD
-1.10 B TWD
-687.19 M TWD
Jan 1, 2024
0.00 TWD
-1.46 B TWD
-744.27 M TWD
Jan 1, 2025
0.00 TWD
-2.86 B TWD
-1.36 B TWD

Lin Bioscience Margins

Lin Bioscience stock margins

The Lin Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lin Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lin Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
100.00 %
- %
- %
Jan 1, 2019
100.00 %
- %
- %
Jan 1, 2020
100.00 %
- %
- %
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %

Lin Bioscience Stock analysis

What does Lin Bioscience do? Lin Bioscience Inc develops drugs in the research and development and clinical trials stage. The company focuses on four major drugs: LBS-008 for dry macular degeneration and stel lesions, LBS-007 for acute leukemia and solid tumors, LBS-009 for NAFLD, NASH, and type 2 diabetes, and LBS-002 for primary and metastatic brain cancer. It also operates two technical platforms, RBP4 for metabolic diseases and CDC7 for all cancers. The company generates revenue through partnerships with pharmaceutical firms for drug development and clinical trials, targeting markets for best-selling drugs and orphan drugs. LBS-008 addresses dry macular degeneration, a best-selling drug category, and stel lesions, an orphan drug segment. LBS-007 targets acute leukemia, an orphan drug market, and solid tumors, a best-selling drug area. LBS-009 covers NAFLD, NASH, and type 2 diabetes, which are high-demand therapeutic areas. LBS-002 focuses on primary and metastatic brain cancer, a niche market. The RBP4 platform serves metabolic diseases, while CDC7 targets all cancers, attracting pharmaceutical companies seeking innovative treatments. Pharmaceutical companies purchase Lin Bioscience's drug development services and technical platforms for their pipeline expansion. These partners include firms specializing in best-selling drugs and orphan drug markets. The company's revenue model relies on licensing agreements and collaborative R&D projects, with a focus on high-growth therapeutic areas like metabolic diseases and oncology. The firm's products align with unmet medical needs in both common and rare conditions. Lin Bioscience is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Lin Bioscience's Profit Margins

The profit margins of Lin Bioscience represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Lin Bioscience's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Lin Bioscience's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Lin Bioscience's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Lin Bioscience’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Lin Bioscience stock

Net Income of Lin Bioscience is -1.36 B TWD in 2025.

Net Income of Lin Bioscience changed from -744.27 M TWD to -1.36 B TWD, representing a 83.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income Lin Bioscience since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Lin Bioscience historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lin Bioscience

All Key Metrics — Lin Bioscience